T
Terrance D. Moore
Researcher at GlaxoSmithKline
Publications - 8
Citations - 855
Terrance D. Moore is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Antibacterial agent & Enoyl-acyl carrier protein reductase. The author has an hindex of 8, co-authored 8 publications receiving 801 citations.
Papers
More filters
Journal ArticleDOI
Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents
David J. Payne,William H. Miller,Valerie Berry,John Brosky,Walter J. Burgess,Emile Chen,Walter E. DeWolf,Andrew P. Fosberry,Rebecca Claire Greenwood,Martha S. Head,Dirk A. Heerding,Cheryl A. Janson,Deborah Dee Jaworski,Paul M. Keller,Manley Peter J,Terrance D. Moore,Kenneth A. Newlander,Stewart C. Pearson,Brian J. Polizzi,Xiayang Qiu,Stephen Rittenhouse,Courtney Slater-Radosti,Kevin L. Salyers,Mark A. Seefeld,Martin G. Smyth,Dennis T. Takata,Irene N. Uzinskas,Kalindi Vaidya,Nicola G. Wallis,Scott B. Winram,Catherine C.K. Yuan,William F. Huffman +31 more
TL;DR: Results show that compound 4 is representative of a new, totally synthetic series of antibacterial agents that has the potential to provide novel alternatives for the treatment of S. aureus infections that are resistant to the present armory of antibiotics.
Journal ArticleDOI
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
Mark A. Seefeld,William H. Miller,Kenneth A. Newlander,Walter J. Burgess,Walter E. DeWolf,Patricia A. Elkins,Martha S. Head,Dalia R. Jakas,Cheryl A. Janson,Paul M. Keller,Manley Peter J,Terrance D. Moore,David J. Payne,Stewart C. Pearson,Brian J. Polizzi,Xiayang Qiu,Stephen Rittenhouse,Irene N. Uzinskas,Nicola G. Wallis,William F. Huffman +19 more
TL;DR: The hypothesis that bacterial enoyl-ACP reductases are valid targets for antibacterial agents is supported, with a new series of inhibitors developed with greatly increased potency against FabI-containing organisms.
Journal ArticleDOI
1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).
Dirk A. Heerding,George M. Chan,Walter E. DeWolf,Andrew P. Fosberry,Cheryl A. Janson,Deborah Dee Jaworski,Edward McManus,William H. Miller,Terrance D. Moore,David J. Payne,Xiayang Qiu,Stephen Rittenhouse,Courtney Slater-Radosti,Ward W. Smith,Dennis T. Takata,Kalindi Vaidya,Catherine C.K. Yuan,William F. Huffman +17 more
TL;DR: 1,4-Disubstituted imidazole inhibitors of Staphylococcus aureus and Escherichia coli enoyl acyl carrier protein reductase (FabI) have been identified.
Journal ArticleDOI
Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
William H. Miller,Mark A. Seefeld,Kenneth A. Newlander,Irene N. Uzinskas,Walter J. Burgess,Dirk A. Heerding,Catherine C.K. Yuan,Martha S. Head,David J. Payne,Stephen Rittenhouse,Terrance D. Moore,Stewart C. Pearson,Valerie Berry,Walter E. DeWolf,Paul M. Keller,Brian J. Polizzi,Xiayang Qiu,Cheryl A. Janson,William F. Huffman +18 more
TL;DR: Results support FabI as a valid antibacterial target and demonstrate the potential of small-molecule FabI inhibitors for the treatment of bacterial infections.
Journal ArticleDOI
Defining and Combating the Mechanisms of Triclosan Resistance in Clinical Isolates of Staphylococcus aureus
Frank Fan,Kang Yan,Nicola G. Wallis,Shannon L. Reed,Terrance D. Moore,Stephen Rittenhouse,Walter E. DeWolf,Jianzhong Huang,Damien McDevitt,William H. Miller,Mark A. Seefeld,Kenneth A. Newlander,Dalia R. Jakas,Martha S. Head,David J. Payne +14 more
TL;DR: Three compounds from a novel chemical series of FabI inhibitors which have excellent activities against both triclosan-resistant and -sensitive clinical isolates of S. aureus are presented.